Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AbCellera Biologics Inc. (ABCL : NSDQ)

• Company Description    AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada. Number of Employees: 596

• Price / Volume Information    Yesterday's Closing Price: $4.61 Daily Weekly Monthly 20 Day Moving Average: 3,753,717 shares Shares Outstanding: 298.83 (millions) Market Capitalization: $1,377.62 (millions) Beta: 0.64 52 Week High: $5.82 52 Week Low: $1.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.44% 0.59% 12 Week 32.85% 20.62% Year To Date 57.34% 40.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 150 W 4TH AVENUE - VANCOUVER,A1 V5Y 1G6 CAN ph: 604-559-9005 fax: - ir@abcellera.com http://www.abcellera.com

• General Corporate Information    Officers Carl L. G. Hansen - Chief Executive Officer and Director Veronique Lecault - Chief Operating Officer and Director Andrew Booth - Chief Financial Officer Michael Hayden - Director John S. Montalbano - Director Peer Information AbCellera Biologics Inc. (CORR.) AbCellera Biologics Inc. (RSPI) AbCellera Biologics Inc. (CGXP) AbCellera Biologics Inc. (BGEN) AbCellera Biologics Inc. (GTBP) AbCellera Biologics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00288U106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/03/25 Share - Related Items Shares Outstanding: 298.83 Most Recent Split Date: (:1) Beta: 0.64 Market Capitalization: $1,377.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.37 Price/Cash Flow: - Price / Sales: 41.90 EPS Growth vs. Year Ago Period: 7.69% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: 133.29% vs. Previous Quarter: 303.40% ROE 06/30/25 - -16.17 03/31/25 - -15.98 12/31/24 - -14.89 ROA 06/30/25 - -12.24 03/31/25 - -12.38 12/31/24 - -11.57 Current Ratio 06/30/25 - 11.07 03/31/25 - 10.15 12/31/24 - 9.81 Quick Ratio 06/30/25 - 11.07 03/31/25 - 10.15 12/31/24 - 9.81 Operating Margin 06/30/25 - -511.88 03/31/25 - -737.56 12/31/24 - -564.81 Net Margin 06/30/25 - -511.88 03/31/25 - -737.56 12/31/24 - -564.81 Pre-Tax Margin 06/30/25 - -604.66 03/31/25 - -911.23 12/31/24 - -695.02 Book Value 06/30/25 - 3.37 03/31/25 - 3.43 12/31/24 - 3.58 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©